Jakob Lochner1, Franka Menge1, Nikolaos Vassos1, Peter Hohenberger1, Bernd Kasper2. 1. Sarcoma Unit, Mannheim University Medical Center, University of Heidelberg, Mannheim, Germany. 2. Sarcoma Unit, Mannheim University Medical Center, University of Heidelberg, Mannheim, Germany, mail@berndkasper.de.
Abstract
OBJECTIVE: The objective of this study was to investigate the prognosis of patients with metastatic soft tissue sarcomas (STS) and to define prognostic indicators for overall survival (OS). METHODS: All patients who were treated at the Sarcoma Unit at the Mannheim University Medical Center between 2010 and 2016 and who developed metastatic disease deriving from a STS were included in this retrospective analysis. OS was investigated using data from clinical records and German registry offices. Clinical and pathological characteristics were recorded and analyzed. RESULTS: A total number of 212 patients developed metastatic disease from STS during that period. Median OS after first documentation of metastatic disease was 24 months (95% CI 21-33). 1-, 2-, and 5-year OS rates were 70.0% (95% CI 64-77), 49.9% (95% CI 43-58), and 24.8% (95% CI 19-33), respectively. In multivariate analysis, significant predictors for mortality appeared to be gender, age, location and size of the primary tumor, histology, and disease-free interval. CONCLUSION: Being treated in a high-volume STS reference center in Germany, patients with metastatic disease could demonstrate an increased OS compared to former analyses. These data can be used as a benchmark for upcoming studies and highlight that further research on treatment strategies in this rare disease is urgently needed.
OBJECTIVE: The objective of this study was to investigate the prognosis of patients with metastatic soft tissue sarcomas (STS) and to define prognostic indicators for overall survival (OS). METHODS: All patients who were treated at the Sarcoma Unit at the Mannheim University Medical Center between 2010 and 2016 and who developed metastatic disease deriving from a STS were included in this retrospective analysis. OS was investigated using data from clinical records and German registry offices. Clinical and pathological characteristics were recorded and analyzed. RESULTS: A total number of 212 patients developed metastatic disease from STS during that period. Median OS after first documentation of metastatic disease was 24 months (95% CI 21-33). 1-, 2-, and 5-year OS rates were 70.0% (95% CI 64-77), 49.9% (95% CI 43-58), and 24.8% (95% CI 19-33), respectively. In multivariate analysis, significant predictors for mortality appeared to be gender, age, location and size of the primary tumor, histology, and disease-free interval. CONCLUSION: Being treated in a high-volume STS reference center in Germany, patients with metastatic disease could demonstrate an increased OS compared to former analyses. These data can be used as a benchmark for upcoming studies and highlight that further research on treatment strategies in this rare disease is urgently needed.
Authors: Andrej Ozaniak; Jitka Smetanova; Robin Bartolini; Michal Rataj; Linda Capkova; Jaromir Hacek; Martina Fialova; Lenka Krupickova; Ilja Striz; Robert Lischke; Jirina Bartunkova; Zuzana Strizova Journal: J Cancer Res Clin Oncol Date: 2022-08-20 Impact factor: 4.322
Authors: Gijsbert M Kalisvaart; Willem Grootjans; Judith V M G Bovée; Hans Gelderblom; Jos A van der Hage; Michiel A J van de Sande; Floris H P van Velden; Johan L Bloem; Lioe-Fee de Geus-Oei Journal: Diagnostics (Basel) Date: 2021-12-04
Authors: Stefan A Koerber; R Finck; K Dendl; M Uhl; T Lindner; C Kratochwil; M Röhrich; H Rathke; G Ungerechts; S Adeberg; K Herfarth; D Jaeger; J Debus; U Haberkorn; F L Giesel Journal: Eur J Nucl Med Mol Imaging Date: 2021-05-21 Impact factor: 9.236